**Amendments to the Claims**

Please cancel Claims 12, 14-15, 26 and 27.

Please amend Claims 1, 3-5, 7-8, 11, 24 and 28-32.

The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1. (Currently Amended) A method of treating inflammation associated with ~~TNFα-mediated~~ viral infection in a human comprising administering to the human an effective TNFα-inhibiting amount of an anti-TNFα antibody or antigen-binding fragment thereof, said antibody comprising a human constant region, wherein said anti-TNFα antibody or antigen-binding fragment thereof (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNFα and (ii) binds to a neutralizing epitope of human TNFα ~~*in vivo*~~ with an affinity of at least 1 x $10^8$ liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.

2. (Canceled).

3. (Currently Amended) A method of treating inflammation associated with ~~TNFα-mediated~~ viral infection in a human comprising administering to the human an effective TNFα-inhibiting amount of an anti-TNFα chimeric monoclonal antibody or antigen-binding fragment thereof, said antibody comprising a human constant region, wherein said anti-TNFα chimeric antibody or antigen-binding fragment thereof (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNFα and (ii) binds to a neutralizing epitope of human TNFα ~~*in vivo*~~ with an affinity of at least 1 x $10^8$ liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.

4. (Currently Amended) A method for treating inflammation associated with ~~TNFα-mediated~~ viral infection in a human comprising administering to the human at least one anti-TNFα chimeric antibody, or an antigen-binding fragment thereof, said anti-TNFα

chimeric antibody comprising a human IgG1 constant region, ~~and~~ wherein said anti-TNFα chimeric antibody or antigen-binding fragment thereof (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNFα and (ii) binds to a neutralizing epitope of human TNFα ~~*in vivo*~~ with an affinity of at least 1 x $10^8$ liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.

5. (Currently Amended) A method of treating inflammation associated with ~~TNFα-mediated~~ viral infection in a human comprising administering to the human an effective TNFα-inhibiting amount of an anti-TNFα antibody or antigen-binding fragment thereof, said anti-TNFα antibody comprising a human IgG1 constant region, ~~and~~ wherein said anti-TNFα antibody or antigen-binding fragment thereof (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNFα and (ii) binds to a neutralizing epitope of human TNFα ~~*in vivo*~~ with an affinity of at least 1 x $10^8$ liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.

6. (Canceled)

7. (Currently Amended) A method of treating inflammation associated with ~~TNFα-mediated~~ viral infection in a human comprising administering to the human an effective TNFα-inhibiting amount of an anti-TNFα chimeric antibody, wherein said anti-TNFα chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.

8. (Currently Amended) A method of treating inflammation associated with ~~TNFα-mediated~~ viral infection in a human comprising administering to the human an effective TNFα-inhibiting amount of an anti-TNFα chimeric antibody, wherein said anti-TNFα chimeric antibody comprises an IgG1 human constant region and a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.

9. (Original) The method of Claim 7 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:4.

10. (Original) The method of Claim 8 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.: 4.

11. (Currently Amended) A method of treating inflammation associated with ~~TNFα-mediated~~ viral infection in a human comprising administering to the human an effective TNFα-inhibiting amount of an anti-TNFα antibody or antigen-binding fragment thereof, said antibody comprising a human constant region, wherein said anti-TNFα antibody or antigen-binding fragment (i) has epitopic specificity identical to A2 (ATCC Accession No. PTA-7045), and (ii) binds to a neutralizing epitope of human TNFα ~~*in vivo*~~ with an affinity of at least 1 x $10^8$ liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.

12-20. (Canceled)

21. (Previously Presented) The method of Claim 1 wherein said anti-TNFα antibody is administered to the human by means of intravenous administration, subcutaneous administration or intramuscular administration.

22 (Canceled).

23. (Previously Presented) The method of Claim 1 wherein said TNFα-inhibiting amount of the anti-TNFα antibody comprises a single or divided dose of about 0.1 - 50 mg/kg.

24. (Currently Amended) The method of Claim 23 wherein said single or divided dose is one selected from ~~the group consisting of: about a 0.1 - 1 mg/kg dose, about a 1.0 - 5 mg/kg dose, about a 5 - 10 mg/kg dose and about a 10 - 20 mg/kg dose~~ 0.5, 0.9, 1, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 mg/kg per day on at least one of day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 or at least one of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

25.-27. (Canceled).

28. (Currently Amended) The method of Claim 1, wherein said ~~TNFα-mediated viral infection is associated with~~ human suffers from alcohol-induced hepatitis.

29. (Currently Amended) The method of Claim 1, wherein said antibody or antigen-binding fragment ~~of Claim 1, which~~ is of immunoglobulin class IgG1, IgG2, IgG3, IgG4 or IgM.

30. (Currently Amended) The method of Claim 1, wherein said antigen-binding fragment ~~of Claim 1, wherein said fragment~~ is selected from the group consisting of Fab, Fab', $F(ab')_2$ and Fv.

31. (Currently Amended) The method of Claim 1, wherein said antibody or antigen-binding fragment ~~of Claim 1, wherein the antibody or antigen-binding fragment~~ comprises a human constant region and a human variable region.

32. (Currently Amended) The method of Claim 1, wherein said antibody or antigen-binding fragment ~~of Claim 1, which~~ comprises at least one human light chain and at least one human heavy chain.